Insulin aspart biphasic

Aspart insulin and biphasic insulin aspart (30% soluble rapid-acting insulin and 70% protamine-bound aspart insulin) have been reviewed (4). 

The new, short-acting insulins can be bound to protamine, allowing the preparation of mixed formulations. In an open, randomized, single-dose, three-way, crossover trial biphasic insulin aspart 30 (30% aspart plus 70% protaminated aspart, BIAsp 30), biphasic insulin lispro 25 (25% lispro plus 75% protaminated lispro, Mix 25), and biphasic human insulin 30 (30% regular plus 70% isophane insulin, BHI 30) were compared in 45 patients (15). Biphasic insulin aspart improved postprandial control better. There were 23 episodes of hypoglycemia with BIAsp 30, 19 with Mix 25, and 11 with BHI 30 two episodes with BIAsp 30, five with Mix 25, and two with BHI 30 required third-party intervention. 

Hermansen K, Colombo M, Storgaard H, O Stergaard A, Kolendorf K, Madsbad S. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care 2002 25(5) 883-8. 

Lindholm A, Jensen LB, Home PD, Raskin P, Boehm BO, Rastam J. Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care 2002 25(5) 876-82. 

Ireland biphasic insulin as-part insulin NovoMix 30 NovomixSO, Novomix70, Novorapid 30Mix Mixture of recombinant insulins, insulin aspart and insulin aspart with protamine Diabetes... 

BWP) 1670 BioTropin 14, 476 Biphasic human insulin 469 Biphasic insulin aspart 470 Biphasic insulin lispro 469 Biphasic porcine insulin 471 Bispecific T cell engager 1175 BiSphere 1305 BiSteel 871 Bitistatin 1283 Bivalent ligand binding 396 Bivalrudin 461... 

McNally PG, Nelson G, Fitch M. Patients with Type 2 diabetes mellitus have lower rates of nocturnal hypoglycaemia on biphasic insulin aspart (BIAsp30) than on biphasic human insulin-30 (BHI30) data from the REACH study. Diabetologia 2004 47 A327. 

Iwamoto Y. A randomised, multicentre trial of biphasic insulin aspart versus biphasic human insulin in Type 2 diabetes. Diabetologia 2003 46 A270. 

Kann PH, Wascher T, Zackova V, Moeller J, Medding J, Szocs A et al. Starting insulin therapy in type 2 diabetes twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes 2006 114(9) 527-532. 

Garber AJ, Wahlen J, Wahl T, Bressler P, Braceras R, Allen E et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab 2006 8(l) 58-66. 

Kilo C, Mezitis N, Jain R, Mersey J, McGill J, Raskin P. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J Diabetes Comphcat 2003 17(6) 307-313. 

Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2... 

Biphasic Insulin Aspart 30% insulin Aspart/70% insulin Aspart protamine 100 units/ml. 

---